RegenETP, Inc. (RGTPQ)
RegenETP, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Salt Lake City, UT, US. The stock last traded at $0.16, up 0.00% on the session, giving a market capitalisation of $1.2M. Its beta of 2.91 implies it has historically moved more than the broad market.
RegenETP, Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Salt Lake City, Utah. This company specializes in advancing and bringing to market a diverse array of regenerative tissue solutions and biological materials across the fields of medicine, biomedical engineering, and materials science within the United States. Its operations are structured into two main divisions: Regenerative Medicine Products and Contract Services. The company's primary offering is SkinTE, an innovative tissue product engineered for the restoration, rebuilding, or augmentation of skin. This therapy is employed in patients to address various conditions such as severe or persistent wounds, burns, post-surgical recovery, scar reduction, or the removal of impaired skin grafts. In addition to its product sales, RegenETP also furnishes specialized contract research services. Currently in its pipeline, the company is developing SkinTE Cryo, which utilizes a cryopreservation method to allow for multiple applications from a single original tissue harvest. It is also progressing a SkinTE point-of-care device, designed to facilitate immediate, on-site processing and application of SkinTE following the initial tissue collection, alongside other future regenerative tissue developments. The company previously operated as PolarityTE, Inc., before rebranding to RegenETP, Inc. in August 2023.
RegenETP, Inc. is most often compared with the following Healthcare names: